Naturally acquired immunity against malaria parasites, which limits high-density parasitemia and severe disease, develops after repeated exposure, and more rapidly in high- than in low-transmission areas \[[@CIT0001], [@CIT0002]\]. This immunity is thought to be primarily mediated by anti--blood stage antibodies, which reduce parasite multiplication and cytoadherence of infected erythrocytes to endothelial cells \[[@CIT0003]\]. In contrast, there is limited evidence for immunological responses preventing blood-stage infection by neutralizing sporozoites and liver-stage parasites \[[@CIT0004], [@CIT0005]\].

Over the past 2 decades, malaria control measures have led to substantial reductions in malaria burden \[[@CIT0006]\], with several endemic countries transitioning from high to low malaria transmission \[[@CIT0007], [@CIT0008]\]. Decreased malaria exposure leads to increased susceptibility to infection and severe disease \[[@CIT0009], [@CIT0010]\] and is associated with decreased levels of antibodies to blood-stage antigens \[[@CIT0011]\].

Controlled human malaria infection (CHMI) of healthy volunteers by exposure to the bites of infected, laboratory-reared *Anopheles* mosquitoes or inoculation of infected erythrocytes has been used for nearly 100 years to investigate malaria pathophysiology and immunology and efficacy of vaccines and drugs \[[@CIT0014], [@CIT0015]\]. During the last decade, CHMI studies have been expanded in the United States and Europe and increasingly performed in Africa using injectable, aseptic, purified, cryopreserved, vialed *Plasmodium falciparum* sporozoites (PfSPZ, Sanaria PfSPZ Challenge) \[[@CIT0005], [@CIT0016]\], including assessment of innate resistance \[[@CIT0005]\], naturally acquired immunity, and preerythrocytic and asexual erythrocytic-stage vaccines \[[@CIT0020], [@CIT0021]\]. In this study we assessed how exposure to *P. falciparum,* as measured by serology to 6 predefined antigens, affected parasite kinetics, clinical symptoms, and functional immunity after CHMI by direct venous inoculation (DVI) of PfSPZ Challenge \[[@CIT0016], [@CIT0017]\] in Gambian men with markedly different levels of previous malarial exposure.

METHODS {#s1}
=======

Study Design and Participants {#s2}
-----------------------------

This was an open-label, nonrandomized clinical trial, conducted at the Medical Research Council Unit The Gambia (MRCG). Healthy male participants aged 18--35 years were recruited between 13 and 23 March 2018. Volunteers were preferentially recruited from tertiary learning institutions and provided written informed consent before screening. Eligible volunteers had normal hematological and biochemical tests and no abnormalities by electrocardiography. Participants had to be *P. falciparum* negative by molecular methods on 2 occasions, at recruitment and just before DVI. Previous individual *P. falciparum* exposure was assessed using serologic responses to a panel of *P. falciparum* antigens using a Luminex platform \[[@CIT0022]\]. These included responses associated with cumulative exposure, namely apical membrane antigen 1 (AMA-1), merozoite surface protein 1.19 (MSP-1.19), and glutamate-rich protein (GLURP.R2) \[[@CIT0023]\], and responses associated with malaria infection in the past 6 months, namely reticulocyte-binding protein homologue (Rh2.2030), gametocyte exported protein (GEXP18), and early transcribed membrane protein (Etramp5.Ag1) \[[@CIT0024]\]. A complete description of the eligibility criteria is provided in [Supplementary Appendix 1](#sup1){ref-type="supplementary-material"}. The study received approval from the Scientific Coordinating Committee of MRCG, The Gambia Government/MRCG Joint Ethics Committee, and the London School of Hygiene and Tropical Medicine Research and Ethics Committee and was conducted according to the International Conference on Harmonisation Good Clinical Practice guidelines and registered with ClinicalTrials.gov (identifier NCT03496454).

Study Objectives {#s3}
----------------

The primary objectives were to assess the feasibility of the CHMI model in The Gambia and determine the parasite kinetics in naturally exposed Gambian adults after PfSPZ Challenge administration. Secondary objectives were to analyze humoral and cellular immune responses and their association with time to patency and parasite density at time of first detection, and to assess the frequency, incidence, nature, and magnitude of adverse events.

PfSPZ Challenge {#s4}
---------------

Sanaria PfSPZ Challenge is composed of aseptic, purified, vialed, cryopreserved, fully infectious NF54 PfSPZ isolated from *Anopheles stephensi* mosquitoes \[[@CIT0016], [@CIT0018], [@CIT0025]\]. PfSPZ Challenge was supplied by Sanaria Inc as 20-µL cyrovials containing 15 000 PfSPZ and stored in liquid nitrogen vapor phase at --150°C to --196°C \[[@CIT0025]\]. For this study, only 1 lot of PfSPZ manufactured on 30 April 2015 was used. The potency (capacity to invade and fully develop in cultured human hepatocytes \[HC-04\]) and viability (sporozoite membrane integrity) of this lot were tested as detailed in [Supplementary Appendix 2](#sup1){ref-type="supplementary-material"}.

Study Procedures {#s5}
----------------

All screened volunteers were ranked by the cumulative quartile score of the mean fluorescence intensities of the 6 predefined antigens \[[@CIT0024]\]. Volunteers with the highest and lowest scores were assigned to the sero-high and sero-low groups, respectively. This classification resulted in significantly higher responses to all individual antigens reflected by mean fluorescence intensities of cumulative and recent exposure markers that were 4- to 13-fold and 3- to 5-fold higher, respectively, in the sero-high group ([Supplementary Appendix 3](#sup1){ref-type="supplementary-material"}). While populations were defined based on a cumulative quartile score for all antigens combined, recognition was also statistically significantly higher for the high exposure population for each of the 6 individual antigens (*P* \< .014) ([Figure 1](#F1){ref-type="fig"}). All volunteers received PfSPZ Challenge (3.2 × 10^3^ PfSPZ in 0.5 mL) by DVI through a 25-gauge needle performed on a single day (29 March 2018) following Sanaria's standard operating procedures. After injection, participants were observed for 1 hour and subsequently closely monitored on an outpatient basis, with regular visits to the study clinic. Participants were instructed to register their daily symptoms in a study diary, measure temperature twice daily, and contact the clinical investigators when any symptoms occurred. From day 5 postinjection onward, participants were seen twice daily until day 15, and daily until day 28 or day of treatment. At each follow-up visit, temperature was taken, adverse events (AEs) were recorded, and blood samples were collected; physical examination was done on indication. Participants had a mobile phone by which they could be contacted. As an additional safety precaution, participants stayed in a hostel close to the study clinic from the day of infection until 3 days after treatment. The following signs and symptoms were solicited at all visits: fever, headache, malaise, fatigue, dizziness, myalgia, arthralgia, nausea, vomiting, chills, diarrhea, abdominal pain, chest pain, palpitations, and shortness of breath \[[@CIT0026]\]. AEs were reported as mild (grade 1, easily tolerated), moderate (grade 2, interfered with normal activity), or severe (grade 3, prevented normal activity); for fever, as grade 1 (\>37.5°C--38.0°C), grade 2 (38.1°C--39.0°C), or grade 3 (≥39.1°C). Laboratory values were graded using the National Institute of Allergy and Infectious Diseases Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1, March 2017.

![Antibody histogram plots for screened volunteers in The Gambia controlled human malaria infection study. Light colors are the sero-low group, dark colors are the sero-high group, and gray colors are the other screened volunteers with intermediate immunological profile. Abbreviations: AMA-1, apical membrane antigen 1; Etramp5.Ag1, early transcribed membrane protein; GEXP18, gametocyte exported protein; GLURP.R2, glutamate-rich protein; MSP-1.19, merozoite surface protein 1.19; Rh2.2030, reticulocyte-binding protein homologue.](ciz740f0001){#F1}

If a thick blood smear (TBS) was positive with any parasitemia, with or without signs and symptoms of malaria, treatment with artemether-lumefantrine was started immediately. Participants who did not develop parasitemia by day 28 received artemether-lumefantrine on that day. Treatment was directly observed, and all participants were seen at day 35 for an end of study visit.

Blood Sampling and Laboratory Assessments {#s6}
-----------------------------------------

Screening for parasitemia by microscopic examination of TBS and quantitative polymerase chain reaction (qPCR) was done twice daily from days 5 to 15 and daily from days 16 to 28. A complete blood count was done the day prior to PfSPZ Challenge injection, every 3 days between days 5 and 28, just before treatment, and thereafter daily for the following 3 days and at day 35. Blood biochemistry was performed 1 day before PfSPZ Challenge injection, 2 days after treatment, and at day 35. To check if volunteers had self-medicated with artemether-lumefantrine, lumefantrine levels were measured at baseline by high-performance liquid chromatography with photodiode array detection \[[@CIT0027]\]. Peripheral blood mononuclear cells were collected for immunological studies 1 day before PfSPZ Challenge injection and at day 35. Malaria infection was defined as asexual parasites in peripheral blood by TBS during the study and by qPCR retrospectively. The prepatent period was defined as the time between PfSPZ Challenge injection and first positive qPCR. Thick blood smears were performed according to an internationally harmonized protocol for thick smears in CHMI studies \[[@CIT0028]\]. qPCR was done retrospectively using established methodologies \[[@CIT0029]\] and considered positive at a parasite threshold of ≥5 parasites per mL.

Immunological Assays {#s7}
--------------------

Assessment of sporozoite invasion inhibition by volunteer serum samples was done as described previously \[[@CIT0030], [@CIT0031]\] and in [Supplementary Appendix 4.](#sup1){ref-type="supplementary-material"} Antibody levels in citrate plasma from volunteers at baseline were measured by enzyme-linked immunosorbent assay (ELISA) to NF54 sporozoite or schizont extract. Growth inhibition was determined by invasion/growth inhibition assays (GIAs) as described in [Supplementary Appendix 4](#sup1){ref-type="supplementary-material"}.

Sample Size Estimation and Statistical Analysis {#s8}
-----------------------------------------------

Sample size calculation was based on the difference in prepatent period between groups. Assuming a mean time to qPCR positivity of 7.1 (standard deviation \[SD\], 0.8\] days \[[@CIT0032]\], it was estimated that 15 participants per cohort would be sufficient to detect a 1-day longer time to first detection of parasites by qPCR in the high-exposure group (8.1 days), with 90% power and α = .05. Due to low numbers of participants presenting for screening and volunteers not meeting eligibility criteria just before study start, only 19 volunteers were enrolled. Prepatent period and parasite density at first detection by qPCR were compared between groups using the log-rank test. For the immunological analyses, differences were assessed by comparing mean values between groups or time points using either a 2-tailed Student *t* test or nonparametric equivalents. Time to patency and parasite density at first detection of infection were associated with immune responses.

RESULTS {#s9}
=======

Study Population {#s10}
----------------

Eighty-four volunteers were screened; of these, 8 were qPCR positive during screening. Nineteen volunteers at the extremes of the immunological spectrum ([Supplementary Appendix 3](#sup1){ref-type="supplementary-material"}) were enrolled into the study: 9 in the sero-high group and 10 in the sero-low group ([Supplementary Appendix 5](#sup1){ref-type="supplementary-material"}). Baseline characteristics are shown in [Table 1](#T1){ref-type="table"}. Most of the volunteers resided in the West Coast region, an area previously reported to have low transmission compared to the other regions \[[@CIT0033]\]. However, malaria transmission in The Gambia is highly heterogenous with both high- and low-exposed individuals in all regions. Volunteers in the sero-high group were older than those in the sero-low group (mean age, 25.7 \[SD, 3.3\] years vs 22.6 \[SD, 2.3\] years, respectively; *P* = .028).

###### 

Demographic Characteristics of Volunteers Enrolled in The Gambia Controlled Human Malaria Infection Study

  Characteristic                 High Exposure Group    Low Exposure Group     *P* Value
  ------------------------------ ---------------------- ---------------------- -----------
  No. of participants            9                      10                     .752
  Age, y, mean (SD)              25.7 (3.3)             22.6 (2.3)             .028
  Male sex, No. (%)              9 (100)                10 (100)               
  Height, cm, median (range)     177.0 (174.0--182.0)   177.0 (174.0--181.0)   .968
  Weight, kg, median (range)     62.8 (59.8--80.1)      64.8 (52.8--86.7)      .490
  BMI, kg/m^2^, median (range)   21.0 (18--26)          20.7 (18--26)          .936
  Ethnicity, No. (%)                                                           
   Mandika                       2 (22.2)               7 (70.0)               .043
   Fula                          5 (55.6)               1 (10.0)               .038
   Other                         2 (22.2)               2 (20.0)               .909
  Residence, No. (%)                                                           
   West Coast region             7 (77.8)               7 (70.0)               .707
   Upper River region            2 (22.2)               0 (0.0)                .125
   Central River region          0 (0.0)                3 (30.0)               .081

Abbreviations: BMI, body mass index; SD, standard deviation.

Parasite Kinetics and Clinical Malaria {#s11}
--------------------------------------

Seventeen of the 19 volunteers (89%) developed parasitemia detected by microscopy in the first 28 days of follow-up: all individuals in the sero-low group (10/10 \[100%\]) and 7 (7/9 \[77.8%\]) in the sero-high group (*P* = .125; [Table 2](#T2){ref-type="table"}). One of the 2 volunteers who remained microscopy negative was qPCR positive at day 18 ([Figure 2A](#F2){ref-type="fig"} and 2B). All volunteers reported no prior or current use of antimalarial drugs and none had measurable concentrations of lumefantrine at baseline. The median prepatent period was significantly shorter in the sero-low than in the sero-high group (9.0 \[SD, 1.6\] days vs 11.0 \[SD, 6.3\] days; log-rank test, *P* = .005) ([Table 2](#T2){ref-type="table"}, [Figure 2B](#F2){ref-type="fig"}). Parasite density by qPCR on day of treatment was significantly higher in the sero-low than in the sero-high group (*P* = .01; [Figure 2C](#F2){ref-type="fig"}). Individual-level parasite kinetics showed faster parasite multiplication in the sero-low group ([Figure 3](#F3){ref-type="fig"}). Parasite multiplication rates were calculated for all available 48-hour intervals (PMR~48~) following first detection of parasites by qPCR until treatment. The median PMR~48~ was nonsignificantly higher in the sero-low group (*P* = .143) and was negatively associated with antibody titers against asexual parasite lysate (*r* = --0.5074, *P* = .0376) ([Supplementary Appendix 6](#sup1){ref-type="supplementary-material"}).

###### 

Parasitological and Clinical Outcomes Following Controlled Human Malaria Infection

  Characteristic                                                 High Exposure Group (n = 9)   Low Exposure Group (n = 10)   *P* Value
  -------------------------------------------------------------- ----------------------------- ----------------------------- -----------
  Subjects positive by microscopy, No. (%)                       7 (77.8)                      10 (100.0)                    .125
  Subjects positive by qPCR, No. (%)                             8 (88.9)                      10 (100.0)                    .292
  Days to parasitemia by microscopy^a^                           14 (6.6)                      13.5 (1.5)                    .327
  Days to parasitemia by qPCR^a^                                 11 (6.3)                      9 (1.6)                       .016
  Days from qPCR positivity to microscopy positivity^a^          3 (2.6)                       5 (0.5)                       .156
  Subjects who developed symptoms^b^, No. (%)                    3 (33.3)                      9 (90.0)                      .013
  Peak parasite density during study (qPCR, parasites/mL)^c^     3748.9 (50.6--71 264.3)       49 340.3 (5186.5--205 850)    .088
  AUC of parasitemia until treatment (qPCR), median (range)^d^   8035 (0--122 054)             34 504 (3404--120 441)        .173

Abbreviations: AUC, area under the curve; qPCR, quantitative polymerase chain reaction (positive at ≥5 parasites/mL).

^a^Median (standard deviation).

^b^Only possibly or probably related to study.

^c^Geometric mean (range).

^d^AUC represents the total parasite exposure over time until treatment (parasite load).

![Comparison of parasite kinetics between the 2 exposure groups following controlled human malaria infection. Kaplan--Meier curve for time from inoculation to parasitemia detected by thick blood smear (*A*) and quantitative polymerase chain reaction (qPCR) (*B*). Differences in parasite density by qPCR at treatment (*C*) and peak parasitemia (*D*).](ciz740f0002){#F2}

![Individual-level kinetics of parasitemia by quantitative polymerase chain reaction (qPCR) following controlled human malaria infection with *Plasmodium falciparum* (*Pf*).](ciz740f0003){#F3}

Participants in the sero-low group had a significantly higher probability of having clinical malaria symptoms (9/10 \[90.0%\]) than those in the sero-high (3/9 \[33%\]) group (log-rank *P* = .0008; [Table 2](#T2){ref-type="table"}, [Figure 4](#F4){ref-type="fig"}).

![Differences in clinical outcomes following controlled human malaria infection in the 2 exposure groups, showing proportion of participants without symptoms, number of adverse events (AEs) per participant, and total number of AEs per group.](ciz740f0004){#F4}

Safety and Tolerability of PfSPZ Challenge {#s12}
------------------------------------------

There were minimal AEs in the first 7 days after PfSPZ Challenge. Fourteen volunteers, 5 in the sero-high (55.6%) and 9 in the sero-low (90.0%) group, experienced 82 AEs, including hematological and biochemistry abnormalities, that were possibly or probably related to malaria ([Table 3](#T3){ref-type="table"}). Seventy of the 82 (85.4%) AEs occurred in the sero-low group, whereas only 12 (14.6%) occurred in the sero-high group (*P* \< .0001). Most AEs (73/82 \[89.0%\]) were mild to moderate and occurred around the time parasitemia became detectable by TBS. Moderate and severe AEs were only observed in the sero-low group ([Table 3](#T3){ref-type="table"}, [Figure 4](#F4){ref-type="fig"}). Headache was the most frequently reported AE in both the sero-high (3/12 \[25%\]) and sero-low (14/70 \[20%\]) groups. Fever was only observed in the sero-low group (5/70 \[7.1%\]) ([Table 3](#T3){ref-type="table"}). Of the 20 hematological and biochemistry abnormalities recorded, 75% (15/20) were in the sero-low and 25.0% (5/20) were in the sero-high group (*P* = .002). No serious AEs or cardiac AEs were reported, and all AEs had resolved by day 35.

###### 

Adverse Events Following Controlled Human Malaria Infection in the 2 Exposure Groups

  Adverse Event                                                   Sero-high Group (n = 9)   Sero-low Group (n = 10)
  --------------------------------------------------------------- ------------------------- -------------------------
  Participants with any AE (including laboratory abnormalities)   5 (55.6)                  9 (90.0)
  Participants with grade 2 or higher AEs                         2 (22.2)                  8 (80.0)
  Total grade 1 and 2 AEs                                         12                        61
   Headache                                                       3 (25.0)                  12 (19.7)
   Fever                                                          0                         5 (8.2)
   Chills                                                         1 (8.3)                   4 (6.6)
   Fatigue/malaise                                                1 (8.3)                   8 (13.1)
   Myalgia                                                        0                         4 (6.6)
   Arthralgia                                                     2 (16.7)                  1 (1.6)
   Anorexia                                                       0                         5 (8.2)
   Nausea                                                         0                         2 (3.3)
   Vomiting                                                       0                         1 (1.6)
   Abdominal pain                                                 0                         2 (3.3)
   Dizziness                                                      0                         3 (4.9)
   Diarrhea                                                       0                         1 (1.6)
   Rib cage pain                                                  0                         1 (1.6)
   Low platelet count                                             1 (8.3)                   2 (3.3)
   Low lymphocyte count                                           1 (8.3)                   5 (8.2)
   Low absolute neutrophil count                                  1 (8.3)                   0
   Elevated total bilirubin                                       0                         2 (3.3)
   Elevated lactate dehydrogenase                                 0                         1 (1.6)
   Elevated AST^a^                                                0                         1 (1.6)
   Elevated γ-glutamyl transferase                                1 (8.3)                   0
   Elevated sodium levels                                         1 (8.3)                   1 (1.6)
  Total grade 3 adverse events                                    0                         9
   Headache                                                       0                         2 (22.2)
   Chills                                                         0                         2 (22.2)
   Fatigue/malaise                                                0                         2 (22.2)
   Low lymphocyte count                                           0                         3 (33.3)

Data are presented as No. (%).

Abbreviations: AE, adverse event; AST, aspartate aminotransferase.

^a^No clinically significant elevations in alanine aminotransferase were observed.

Humoral and Functional Immunity {#s13}
-------------------------------

Antibody recognition of sporozoites by sporozoite-binding ELISA was significantly higher in plasma of sero-high (median, 17.93 \[interquartile range {IQR}, 12.95--24\] arbitrary units \[AU\]) compared to the sero-low volunteers (median, 10.54 \[IQR, 8.36--12.12\] AU) (*P* = .006; [Figure 5A](#F5){ref-type="fig"}). However, the groups did not differ in their ability to block sporozoite invasion of HC04 hepatocytes, (sero-high: median 88.26% invasion \[IQR, 83.52%--100.1%\]; sero-low: 91.74% invasion \[IQR, 90.54%--103%\]) (*P* = .18; [Figure 5B](#F5){ref-type="fig"}). Invasion was indexed as a percentage relative to invasion in the presence of nonimmune serum from naive donors, where 100% meant no invasion inhibition. The presence of blood-stage antibodies, determined by schizont extract, was also significantly higher (*P* = .0003) in the sero-high group (median, 50.98 \[IQR, 22.46--65.07\] AU; [Figure 5C](#F5){ref-type="fig"}) than in the sero-low group (median, 3.16 \[IQR, 2.43--8.71\] AU). We observed indications for functional differences in blood-stage immune responses, with significantly higher GIA in the sero-high (median, 21.8% \[IQR, 8.15%--29.65%\]) than in the sero-low (median, 8.3% \[IQR, 5.6%--10.23%\]) (*P* = .025; [Figure 5D](#F5){ref-type="fig"}). Length of prepatent period correlated positively with sporozoite-binding antibody titers (*r* = 0.64, *P* = .003), blood-stage antibody titers (*r* = 0.48, *P* = .036), and blood-stage GIA activity (*r* = 0.65, *P* = .003) but not with sporozoite invasion inhibition (*r* = --0.29, *P* = .236). For individual antibody responses, Rh2.2030 (*r* = 0.5357, *P* = .018) and AMA-1 (*r* = 0.4959, *P* = .031) were the most predictive of prepatent period ([Supplementary Appendix 7](#sup1){ref-type="supplementary-material"}). Significant correlation was also seen between the different immunological responses ([Supplementary Appendix 8](#sup1){ref-type="supplementary-material"}).

![Antibody-mediated responses to *Plasmodium falciparum* in high- and low-exposure groups. *A*, The sero-high group had significantly higher (*P* = .006) titers of antibodies to sporozoite antigens, expressed as arbitrary units (AU). *B*, There were no significant differences between groups in their ability to block sporozoite invasion of HC04 hepatocytes. *C*, Plasma from the sero-high group also had significantly higher (*P* = .0003) levels of antibodies to asexual-stage antigens, also expressed as AU. *D*, Purified immunoglobulin G from the sero-high exposure group also had significantly higher growth inhibitory activity (*P* = .025) against blood-stage 3D7 parasites.](ciz740f0005){#F5}

DISCUSSION {#s14}
==========

This study demonstrated the feasibility and successful implementation of CHMI with PfSPZ Challenge in The Gambia, increasing the capacity of conducting such studies in endemic areas: CHMI with PfSPZ Challenge has now been done in 6 African countries \[[@CIT0005], [@CIT0018]\]. A study in Gabon with PfSPZ Challenge reported that previous exposure to both *P. falciparum* and sickle cell trait impacted the rate of blood-stage infection, prepatent period, and clinical manifestations of malaria \[[@CIT0005]\]. While previous studies in Kenya also associated immune responses to parasite kinetics among CHMI volunteers \[[@CIT0034]\], ours is the first assessment of the effect of previous exposure to *P. falciparum* as measured by a predefined serology panel of 6 antigens on parasite kinetics, clinical symptoms, and functional immune responses. Individuals with serological evidence of higher recent and cumulative malaria exposure had a longer prepatent period, lower mean parasite density, and fewer symptoms of malaria. Whereas there was considerable variability in individual responses, the prescreening panel used to define exposure in this population correlated directly with clinical outcomes \[[@CIT0022]\]. Using functional assays for preerythrocytic immunity and blood-stage immunity, this study also sheds light on the mechanisms underlying these differences. Antisporozoite responses were higher in highly exposed individuals but did not translate into responses preventing liver-stage infection in vitro while antibody responses controlling blood-stage parasite multiplication in vitro were markedly stronger in this group.

Understanding the impact of declining malaria exposure on malaria immunity is highly relevant in the context of widescale and often pronounced reductions in malaria burden in African and non-African settings \[[@CIT0035], [@CIT0036]\]. More direct methods for assessing immunity are needed to quantify the clinical consequences of declined exposure. While we directly defined our cohorts based on serological markers that have been presented as indicators of recent and cumulative exposure \[[@CIT0024], [@CIT0037]\], several previous studies have indirectly determined malaria exposure based on self-reported clinical history of malaria episodes and long-term residence in malaria-endemic areas \[[@CIT0005], [@CIT0023]\] or by measuring responses to whole parasite lysate and the blood-stage antigen MSP-2 with a very long half-life \[[@CIT0038]\]. In line with our findings, these studies observed a lower likelihood of parasite positivity post-CHMI in the highly exposed group \[[@CIT0005], [@CIT0023], [@CIT0038]\]. Lell and colleagues postulated that mechanisms for the control of parasitemia included a combination of adaptive immune mechanisms such as prevention of hepatocyte infection, elimination of infected liver cells by T-cell--mediated cytotoxicity or immune mediators, and highly effective clearance of the first generation of merozoites leaving infected hepatocytes \[[@CIT0005]\]. Our study directly examined differences in functional preerythrocytic and blood-stage immunity using established methodologies. Though we found no evidence for differences in inhibition of sporozoite invasion, we observed stronger parasite growth inhibition in the sero-high cohort. As volunteers were selected based on distinct immune profiles, our functional immune parameters must be interpreted with caution given challenges in disentangling functional immune responses from markers of exposure \[[@CIT0039]\]. The single volunteer who remained parasite-negative by qPCR had median levels of preerythrocytic antibodies (17.93 AU), moderate HC04 invasion (104.13%; mean, 95.41% invasion), very low levels of asexual antibodies (5.98 AU; mean, 47.42 AU), and average GIA (23% inhibition; mean, 21.94%). The striking difference in growth inhibition in our 2 cohorts suggests that functional blood-stage antibodies contributed significantly to the differences in clinical symptoms and parasite kinetics. There was a weak, negative correlation (*r* = --0.4474, *P* = .0548) between levels of sporozoite-binding antibodies and functional invasion-blocking activity, suggesting a minor invasion-blocking role for naturally acquired antibodies. Sporozoite-targeting antibodies in this study may be markers of exposure only or may enhance cellular immunity but lack direct invasion-blocking activity.

The systemic and laboratory AEs observed were consistent with uncomplicated malaria, with most AEs recorded at the time of positive microscopy. Severe symptoms, including chills, fatigue, malaise, and headache reported in 3 sero-low volunteers, were also consistent with uncomplicated malaria and resolved within 48 hours posttreatment. Two sero-low volunteers had grade 3 reductions in total lymphocyte count considered related to malaria and resolved by day 4 of malaria treatment. Similar declines have been reported previously \[[@CIT0040]\]. This study does not allow us to extrapolate findings to other populations.

In summary, CHMI was safe and well tolerated in this population and the manifestations of malaria, although significantly different between the 2 exposure groups, were consistent with previous CHMI studies. Volunteers with high previous exposure to malaria infection were able to better control the infection as shown by the significantly lower parasite densities, less-severe symptoms, and lower incidence of symptoms associated with parasitemia.

Supplementary Data {#s15}
==================

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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